Given this, together with the association between more BG‐EPVS and lower tau deposition, especially in CI or Aβ‐positive individuals, our results suggest that, while overall BG‐EPVS burden increases with cognitive decline or progression of Alzheimer's disease, elevated BG‐EPVS themselves may reduce tau pathology by facilitating clearance of tau proteins under CI conditions. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.